CytoSorbents is commercializing its E.U. approved CytoSorb blood purification technology to treat life-threatening conditions in the intensive care unit and cardiac surgery. The company also seeks U.S. and Canadian approval of a second product, DrugSorb-ATR, to reduce perioperative bleeding risk in patients on blood thinners in cardiac surgery. After FDA denial in April 2025, the company plans to submit a new De Novo application to the FDA in 2026. Based on $37.1 million in high margin 2025 revenue and the DrugSorb-ATR potential in 2026-27, we believe CTSO stock to be significantly undervalued at this time.